ABUS vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 02, 2026

ABUS

51.2
AI Score
VS
ABUS Wins

CDNA

44.7
AI Score

Investment Advisor Scores

ABUS

51score
Recommendation
HOLD

CDNA

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ABUS CDNA Winner
Revenue 179.13M 249.65M CDNA
Net Income 169.69M 113.44M ABUS
Net Margin 94.7% 45.4% ABUS
Operating Income 168.91M 114.42M ABUS
ROE 65.2% 26.7% ABUS
ROA 61.2% 21.3% ABUS
Total Assets 277.16M 532.99M CDNA
Cash 23.71M 373.64M CDNA
Current Ratio 54.26 4.58 ABUS

Relative Price Performance (Last 90 Days)

ABUS 1M: -8.2% · 3M: +3.3% CDNA 1M: +49.4% · 3M: +110.0%

Current Technical Phase

ABUS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 43.5 · Price: $4.34

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (23.4% over 20 days), RSI 77

RSI (14): 77.4 · Price: $43.71

Fundamentals Snapshot

Metric ABUS CDNA
Market Cap
Forward P/E -35.0 38.5
Trailing P/E 5.1
Revenue (TTM)
Revenue Growth 100.5% 0.4%
Gross Margin 0.9% 0.7%
Operating Margin 0.9% 0.0%
EPS 0.86 -0.17
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ABUS is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.